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Recent progress in the field of aging has resulted in ever increasing numbers
of compounds that extend lifespan in Caenorhabditis elegans. Lifespan extending
compounds include metabolites and synthetic compounds, as well as natural products. For
many of these compounds, mammalian pharmacology is known, and for some the actual
targets have been experimentally identified. In this review, we explore the data available
in C. elegans to provide an overview of which pharmacological classes have potential for
identification of further compounds that extend lifespan.
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INTRODUCTION
As a consequence of the seminal discoveries demonstrating that
lifespan can be modulated by genes, it became clear that lifespan
might also be extended using chemicals (Johnson, 1990; Kenyon
et al., 1993). This concept has certainly been demonstrated, and
today many compounds have been identified that extend lifespan
in model organisms such as worms, flies and even mice (Kang
et al., 2002; Howitz et al., 2003; Evason et al., 2005; Baur et al.,
2006; Wilson et al., 2006; Petrascheck et al., 2007; Benedetti
et al., 2008; McColl et al., 2008; Harrison et al., 2009; Pietsch
et al., 2009; Alavez et al., 2011; Moskalev and Shaposhnikov,
2011; Oxenkrug et al., 2012; Martin-Montalvo et al., 2013; Priebe
et al., 2013; Ye et al., 2014). Among all of these model organisms,
Caenorhabditis elegans stands out because of the large variety
of compounds known to extend lifespan. It is now possible to
group these compounds into pharmacological classes, and use
these groupings as starting points to search for additional lifespan
extending compounds.
In the following paragraphs, we will give a short overview of
what is known about the pharmacology of lifespan extension in
C. elegans. We will summarize the discovery of lifespan extending
compounds, comment on problems associated with the inter-
pretation of pharmacological data, and we will end with a dis-
cussion of specific pharmacological classes of lifespan extending
compounds.
DISCOVERING LIFESPAN EXTENDING COMPOUNDS
There are two fundamentally different approaches to identify
compounds that have a desired biological effect. These two
approaches are often referred to as forward and reverse phar-
macology, analogous to forward and reverse genetics (Bartfai,
2006). Forward pharmacology approaches, also called phenotypic
screens, screen for compounds that elicit a desired phenotype,
like the extension of lifespan. While forward pharmacology is
intuitively appealing, as it searches for the desired effect, it has
a number of drawbacks. The first is that screens must gen-
erally be conducted in vivo. In vivo screens are more com-
plex, generally longer, and have higher costs associated than in
vitro screens. Even if these disadvantages are overcome, eluci-
dating the mechanisms by which a hit-compound achieves the
desired effect is difficult. Elucidating drug mechanisms gener-
ally requires the identification of the drug target, which even
today represents a major challenge (i.e., the binding target of the
compound).
Reverse pharmacology circumvents the problem of target iden-
tification by screening for compounds that bind to, or inhibit,
the function of a specific protein target. Reverse pharmacology
screens are largely done in vitro, and offer the ability to screen very
large chemical libraries (+500,000). Targets are validated based
on prior knowledge, such as genetic studies in model organisms
or gene association studies in humans affected by the disease.
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However, target validation, or choosing the protein target against
which to develop a drug, also poses considerable difficulties
(Pankevich et al., 2014).
As the process of aging is not easily replicated in vitro, most
lifespan extending compounds have been identified by simply
testing whether or not a given compound extends lifespan in
a model organism (forward pharmacology). Thus far, most
compounds that have been tested for their ability to extend lifes-
pan had prior known pharmacology. Initially, these compounds
were developed to inhibit a specific target, independent of their
effect on aging. Only later were they tested for their ability to
extend lifespan in C. elegans or other organisms. Thus, at its
current state, the pharmacology of aging is a hybrid of forward
and reverse pharmacology.
Why is the pharmacology of aging a hybrid of these two
approaches? The simple answer is that it suffers from the dis-
advantages of both approaches. Target validation is problematic
because most of the genes thus far found to be involved in
the determination of lifespan are either essential, or they affect
mitochondrial biology, insulin signaling, or general metabolism
(Lee et al., 2003; Curran and Ruvkun, 2007; Hansen et al.,
2007; Smith et al., 2008). These are difficult targets, as any
lifespan extending compound will be given to old and frail peo-
ple over extended periods of time, and therefore demands an
extremely good safety profile. The history of the development
of anti-obesity drugs has shown how difficult it is to choose
an appropriate target to modulate metabolism in safe ways.
While the example of metformin shows that it is possible to
safely modulate insulin and/or general metabolism (Onken and
Driscoll, 2010; Martin-Montalvo et al., 2013), we should note
that the glucose lowering effects of metformin were discovered
accidently through malaria research and not by a screen based
on a validated target (Bailey and Day, 2004; Madiraju et al.,
2014)
The forward pharmacology approach has logistical problems.
Screens for lifespan in mammals are prohibitively expensive, and
thus screens must be conducted in small model organisms. Even
for C. elegans, maintaining, treating, and scoring thousands of
cohorts of animals to determine their lifespan is inherently diffi-
cult, as even small irregularities have considerable effects on lifes-
pan. For these reasons, few medium (>1000) to large (>10,000)
screens have been performed using diverse compound libraries
(Petrascheck et al., 2007; Ye et al., 2014). Lifespan data in and of
themselves are problematic, as they are non-normally distributed,
and Z’ statistics generally used to evaluate other screens are not
appropriate (Zhang et al., 1999). Thus, unless some groundbreak-
ing technical advances are made, the pharmacology of aging is
likely to remain a hybrid of forward and reverse pharmacology
for the foreseeable future.
Early studies in C. elegans used extremely high concentrations
of chemicals, creating the impression that worms were espe-
cially resistant. However, today many of the lifespan extending
compounds are effective at concentrations in the lower micro-
molar range (Luciani et al., 2011; Ye et al., 2014). When com-
pared to cell culture, these concentrations still seem high, but
compared to mouse studies they are not. Drug injections are
generally conducted at concentrations of 5–200 mg/kg, resulting
in an internal concentration in the lower micromolar range
(Hayashi and McMahon, 2002). As concentrations for C. elegans
are indicated for the external culture medium, the internal con-
centrations are likely to be lower and thus similar to those in
mice.
Interpreting lifespan data obtained from compounds with
known pharmacology has its own pitfalls. The pharmacological
data available for most lifespan extending compounds are based
on human data, while the lifespan data are based on experiments
in model organisms (Knox et al., 2011). How well pharmacology
between species is conserved is unknown, as we have no method
to determine all protein targets of a compound. It may well be
that a compound annotated as an inhibitor for a specific kinase
extends lifespan by inhibiting an off-target.
Thus, after the identification of a lifespan extending com-
pound, it is important to test multiple, structurally different
compounds with the same pharmacology. If several structurally
different compounds with the same pharmacology extend lifes-
pan, the lifespan extending effect is likely to come from the
annotated target, since off targets tend to be different for different
structures. For example, multiple serotonergic antagonists extend
C. elegans lifespan irrespective of their structure (Ye et al., 2014).
Furthermore, combining structural studies with genetic studies,
in which the compound is tested on mutants lacking the suspected
target, allows the identification of the compound target with a
high degree of certainty.
Given these caveats, we will discuss only pharmacological
classes for which (i) multiple compounds were identified and (ii)
additional genetic data exist that support the notion that targeting
this class of proteins will lead to a lifespan extension. The genetic
data we considered include mutations in target proteins that
either cause a lifespan extension or, as is often the case, abrogate
the lifespan extending effect of the compound. As an exception,
we include natural compounds because of their general interest
and wide use as food-supplements.
PHARMACOLOGICAL CLASSES THAT EXTEND LIFESPAN
ANTIOXIDANTS
Because of Harman’s theory of oxidative stress, antioxidants were
some of the first compounds to be tested for their ability to
extend lifespan and, as a compound class, have received quite
a bit of attention (Harman, 1972; Melov et al., 2000; Benedetti
et al., 2008). Indeed, antioxidants that extend C. elegans lifes-
pan have been identified. These findings initially lent support
to the idea that oxidative stress causes aging. However, later
experiments guided by the theory of hormesis have challenged
this view of aging. The theory of hormesis predicts that low
levels of stress extend lifespan by over-activating stress responses,
leading to excess stress response capacity and thus stress resistance
and long-lived animals. Several reactive oxygen species (ROS)
generating compounds such as rotenone, paraquat, arsenite, or
naphthoquinone derivatives, were found to extend lifespan of
C. elegans when used at low concentrations (Schulz et al., 2007;
Van Raamsdonk and Hekimi, 2009; Lee et al., 2010; Hunt et al.,
2011). Surprisingly, antioxidants blocked the lifespan extension
of many hormetic agents, clearly suggesting that oxidative stress
was required for the lifespan extension. Therefore, evidence
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exists that antioxidants extend lifespan and, paradoxically, also
abrogate lifespan extension by hormetic agents. How can these
findings be unified? One argument is that, although a com-
pound has antioxidant capabilities, it still may extend lifespan
by blocking an enzymatic activity independent of the antiox-
idant effect. This may indeed be true for some antioxidants.
However, given the evidence that oxidative stress increases with
age, it is unlikely to be true for all antioxidants. An interesting
alternative that could explain how oxidants (hormetic agents)
as well as antioxidants extend lifespan is to hypothesize that
redox regulation plays an important role in determining lifes-
pan. For example, many proteins known to be involved in
aging (e.g., DNA repair enzymes) contain reactive cysteines
whose redox status may alter protein activity (Weerapana et al.,
2010).
While lifespan extending antioxidants were found based on
candidate approaches, unbiased screens testing many pharmaco-
logical classes for their ability to extend C. elegans lifespan did
not result in any lifespan extending antioxidants. This observation
suggests that, as a pharmacological class, antioxidants may not
be a particularly strong candidate for identification of lifespan
extending compounds (Ye et al., 2014).
METABOLITES
The first ever intervention found to verifiably extend lifespan was
dietary restriction. Thus, dietary restriction immediately linked
the process of aging to metabolism. In recent years, metabo-
lites have received increased interest, due in part to technical
advances in metabolomics and the identification of metabolic
enzymes important in the determination of lifespan. Today, mul-
tiple metabolites are known that play a role in the determi-
nation of adult lifespan. These include the nuclear hormone
receptor ligand dafachronic acid, ascarosides (ascr#2, ascr#3),
N-acylethanolamines, and α-ketoglutarate (Motola et al., 2006;
Lucanic et al., 2011; von Reuss et al., 2012; Ludewig et al., 2013;
Priebe et al., 2013; Chin et al., 2014).
Ascarosides are endogenously produced compounds that are
derived from the dideoxy sugar ascarylose, and were discovered
as high population density signals. They affect many aspects of
C. elegans physiology. For example, the lifespan extension of
ascr#2 is mediated by the G-protein coupled receptor (GPCR)
DAF-37, specifically expressed in the nervous system. This is
an excellent example of how environmental signals are able
to affect longevity via the nervous system (von Reuss et al.,
2012).
Dafachronic acids are bile-acid-like steroids that are ligands for
nuclear hormone receptors and are synthesized in starving ani-
mals. In adult C. elegans, dafachronic acids directly or indirectly
activate NHR-8, leading to a reduction in let-363/mTOR expres-
sion and subsequent longevity (Motola et al., 2006; Thondamal
et al., 2014).
Similarly, the tricarboxylic acid cycle intermediate α-
ketoglutarate appears to mediate dietary restriction induced
lifespan extension. Starvation induces α-ketoglutarate synthesis,
which then blocks the ATP synthase, leading to reduced oxygen
consumption, reduced ATP synthesis and increased autophagy
(Chin et al., 2014).
In contrast, N-acylethanolamines, a class of fatty acid amides,
are synthesized under favorable conditions. While high levels
of N-acylethanolamines block lifespan extensions by dietary
restriction, low levels of N-acylethanolamines are found under
conditions of dietary restriction and are sufficient to extend
lifespan (Lucanic et al., 2011). There are still few metabo-
lites known to regulate lifespan, but the aforementioned exam-
ples show that the metabolome is likely to contain many
more interesting compounds involved in the regulation of
lifespan.
KINASE INHIBITORS
The first cloned gene found to be important for lifespan determi-
nation was the class-I phosphatidylinositol 3-kinase age-1 (Mor-
ris et al., 1996). In addition to age-1, numerous mutations in
various kinases have been found to extend C. elegans lifespan,
including the receptor tyrosine kinase daf-2, akt-1, TOR, and
S6 kinase, to name a few. Mutations in kinases like age-1 and
the insulin/IGF receptor daf-2 cause some of the most dramatic
effects on lifespan. As mutations in kinases are also frequently
found in cancers and other diseases (Vogt et al., 2010) many
kinase inhibitors were found to extend C. elegans lifespan (e.g.,
lithium, GDC-0941, LFM-A13, and rapamycin), with the most
promising being rapamycin (Harrison et al., 2009; Ye et al., 2014).
However, thus far none of the tested kinase inhibitors has been
able to reproduce the spectacular longevity seen in age-1 or daf-
2 mutants. For example, PI3kinase inhibitors like GDC-0941 do
increase C. elegans lifespan, but only by about 10%, while the
most extreme age-1 mutant alleles increase lifespan by 700% or
more (Ayyadevara et al., 2008; Bharill et al., 2013). Similarly the
IIS (daf-2) inhibitor NT219 blocks IIS signaling in C. elegans, but
does not extend lifespan (El-Ami et al., 2014). It is unclear why
these kinase inhibitors are unable to mimic the effect of genetic
mutations. Possible explanations include: (i) the kinase inhibitors
are not specific enough, and thus cause side effects masking
longevity, (ii) inhibiting the kinase activity only is insufficient,
(iii) longevity in the mutants is partially due to altered develop-
ment. These three possibilities are testable and, while currently the
answer is not known, it should be possible to clarify these issues
soon.
NUCLEAR HORMONE RECEPTORS
Nuclear hormone receptors are an important class of regula-
tory proteins that activate or repress gene expression patterns in
response to cellular signals. The fact that these signals generally
consist of small molecules, like steroid hormones, makes nuclear
hormone receptors important drugs targets. Because of the early
discovery of the role of DAF-12 in the determination of lifespan,
hormonal regulation of lifespan has been a central theme in aging.
Candidate approaches, as well as unbiased screens of synthetic
compounds have identified lifespan extending compounds known
to bind nuclear hormone receptors. One problem with studying
nuclear hormone receptors using C. elegans is its vastly expanded
repertoire of 284 nuclear hormone receptors, compared to 49
in mammals (Antebi et al., 2000; Robinson-Rechavi et al., 2001;
Motola et al., 2006) making it difficult to translate C.elegans
findings to mammals.
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G PROTEIN COUPLED RECEPTOR LIGANDS
Compounds affecting GPCR are among the most important
pharmacological classes for drug discovery (Paolini et al., 2006;
Yildirim et al., 2007). In medium scale screens for compounds
with known pharmacology that extend lifespan, 50% of all hit
compounds targeted GPCRs (Ye et al., 2014). This was surprising,
as the genome wide RNAi screens only uncovered one GPCR
as being involved in the regulation of lifespan (Lee et al., 2003;
Hansen et al., 2007). How can these findings be unified? One
explanation may be a technical difference. The RNAi screens
started to inhibit gene expression early in development, while
the chemical screens started inhibition during adulthood. Indeed,
the lifespan extending effect of Mianserin was reduced from
+33% to less than 10% when added to developing animals
rather than adult animals (Petrascheck et al., 2007). This result
suggests that GPCRs signal environmental changes, upon which
the physiology of the animal adapts. Thus, blocking signaling
in adults causes a change that leads to alterations in physiol-
ogy, while a continuous repression starting in early develop-
ment does not. While considered “accidental” pharmacology,
finding bioactive compounds by chance often results in com-
pounds targeting GPCRs. Examples include Cannabinoid recep-
tors, Opioid receptors, and dopamine receptors to name a few.
By contrast, forward genetic screens, which result in the perma-
nent inhibition of a GPCR, have only identified a handful of
GPCRs. Out of roughly 6000 C. elegans genes cloned, only five
were GPCRs, despite the fact that GPCRs represent 5% of the
entire genome (Moresco and Koelle, 2004). Thus, it appears that
GPCRs exist that must be active during development in order
to affect lifespan when blocked in adults, probably because their
function is to modulate lifespan in response to environmental
change.
NATURAL COMPOUNDS
Many natural compounds or plant extracts such as blueberry
polyphenols, curcumin, quercetin, ginkgo extracts, and resvera-
trol have been identified to extend C. elegans lifespan (Wu et al.,
2002; Howitz et al., 2003; Wilson et al., 2006; Pietsch et al., 2009).
What makes a natural compound approach attractive is that plant
extracts are generally regarded as safe, and are often used as food
supplements. However, natural compounds are hard to synthesize
and modify, and thus target identification is particularly difficult
for natural compounds. The ongoing dispute on the mecha-
nism of action of resveratrol certainly gives testimony on such
difficulties. The proposed mechanisms range from antioxidant
properties, to activation of the histone deacetylase SIRT1, AMPK
activation by blocking phosphodiesterase activity, or mimicking
tyrosine-activating stress response pathways via TyrRS and PARP1
(Howitz et al., 2003; Park et al., 2012; Sajish and Schimmel,
2014).
SUMMARY
In this short review, we have discussed how lifespan extending
compounds are currently identified, what limits progress, and
which pharmacological actions seem to extend lifespan. Dis-
cussing the different classes above shows that lifespan phar-
macology is not inherently different from any other type of
drug discovery. It seems that the same pharmacological classes
(GPCR’s, nuclear hormone receptors, Kinases) that delivered
compounds for many other indications are also suitable for
lifespan extension. It may, however, be that our conclusions are
biased for historical reasons. Most of the compounds tested for
lifespan were those that were readily available, which are the same
compounds that stand out as promising for other indications.
Alternatively, it is also possible that GPCRs, nuclear hormone
receptors, kinases, and ion-channels make better drug targets.
This may be because all these proteins exert regulatory func-
tions, affect multiple physiological functions, and may also be
easier to target with drugs than others. Whatever the reasons,
the large overlap between pharmacological classes that extend
C. elegans lifespan and drugs used in humans is encouraging
because it suggests that some degree of conservation can be
expected.
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